Compass Therapeutics (CMPX) returns
Compass Therapeutics returns over 5 years
$1,000 invested in Compass Therapeutics five years ago was worth $260.43 at the close on October 30, 2026, with dividends reinvested: an average return of -23.6% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -24.4% | — | $756.25 | -0.9% |
| 3 months | -59.5% | — | $405.41 | +2.1% |
| Year to date | -85.4% | — | $146.46 | +11.7% |
| 1 year | -78.9% | — | $211.42 | +12.4% |
| 3 years | -55.6% | -23.7% | $444.35 | +88.5% |
| 5 years | -74.0% | -23.6% | $260.43 | +76.0% |
Compass Therapeutics return by calendar year
| Year | CMPX | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -85.4% | +11.7% | -97.0% |
| 2025 | +270.3% | +17.7% | +252.6% |
| 2024 | -7.1% | +24.9% | -31.9% |
| 2023 | -69.0% | +26.2% | -95.2% |
| 2022 | +58.7% | -18.2% | +76.8% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also:
No forecast, no recommendation. This page describes Compass Therapeutics from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.